Morrison G A, Evans J N
Department of Otolaryngology, Hospitals for Sick Children, London, UK.
Int J Pediatr Otorhinolaryngol. 1993 Mar;26(2):193-7. doi: 10.1016/0165-5876(93)90027-z.
Four patients with aggressive respiratory papillomatosis have been treated with oral Acyclovir as adjuvant therapy while continuing to undergo regular endoscopy and laser treatment to the lesions. The duration of Acyclovir administration ranged from 2 weeks to 3 months. Two patients had papillomatosis confined to the larynx and two in addition had disease in the lower respiratory tract. One of the four patients had less aggressive disease during the treatment period. Acyclovir does not appear to significantly influence respiratory papillomatosis. Acyclovir's activity is dependent upon the presence of virally encoded thymidine kinase. This enzyme is not known to be encoded by papilloma viruses. Acyclovir is not recommended in the treatment of juvenile respiratory papillomatosis.
四名侵袭性呼吸道乳头状瘤病患者接受了口服阿昔洛韦作为辅助治疗，同时继续接受定期内镜检查和对病变进行激光治疗。阿昔洛韦的给药持续时间为2周至3个月。两名患者的乳头状瘤病局限于喉部，另外两名患者的下呼吸道也有病变。四名患者中有一名在治疗期间病情侵袭性较低。阿昔洛韦似乎不会对呼吸道乳头状瘤病产生显著影响。阿昔洛韦的活性取决于病毒编码的胸苷激酶的存在。目前尚不清楚这种酶是否由乳头瘤病毒编码。不推荐使用阿昔洛韦治疗青少年呼吸道乳头状瘤病。
